Pharming Group N.V. (PHAR) Q1 2025 Earnings
PHAR·Reported May 8, 2025·Before market open
Pharming Group N.V. reported Q1 2025 revenue of $86.7M, beat analyst consensus of $72.7M by $14.0M. Diluted EPS came in at $-0.22, beat the $-0.25 consensus by $0.03.
Revenue
$86.7Mbeat by $14.0M
Consensus: $72.7MDiluted EPS
$-0.22beat by $0.03
Consensus: $-0.25
SEC Filings
Earnings release8-K not filed yet
Quarterly report10-Q / 10-K not filed yet
Filings will appear here once submitted to SEC EDGAR.
Q1 2025 Earnings FAQ
Common questions about Pharming Group N.V.'s Q1 2025 earnings report.
Pharming Group N.V. (PHAR) reported Q1 2025 earnings on May 8, 2025 before market open.
Pharming Group N.V. reported revenue of $86.7M and diluted EPS of $-0.22 for Q1 2025.
Revenue beat the consensus estimate of $72.7M by $14.0M. EPS beat the consensus estimate of $-0.25 by $0.03.